There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), Arvinas Holding Company (ARVN – Research Report) and Progyny (PGNY – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co today and set a price target of $875.00. The company’s shares closed last Thursday at $776.42, close to its 52-week high of $800.78.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $881.00, representing a 12.3% upside. In a report issued on May 1, Barclays also maintained a Buy rating on the stock with a $913.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Arvinas Holding Company (ARVN)
In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Arvinas Holding Company, with a price target of $60.00. The company’s shares closed last Thursday at $33.04.
According to TipRanks.com, Archila is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arvinas Holding Company with a $65.25 average price target, which is a 92.6% upside from current levels. In a report issued on May 8, Wedbush also initiated coverage with a Buy rating on the stock with a $57.00 price target.
Progyny (PGNY)
In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on Progyny, with a price target of $37.00. The company’s shares closed last Thursday at $27.72.
According to TipRanks.com, Lutz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $37.86, which is a 41.2% upside from current levels. In a report issued on May 9, BTIG also maintained a Buy rating on the stock with a $41.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LLY:
- Jefferies retail/healthcare analysts to hold an analyst/industry conference call
- Eli Lilly announces retirement of Chief Ethics and Compliance Officer Weems
- New Analyst Adjustments Prove Little Help to Eli Lilly (NYSE:LLY)
- Eli Lilly price target raised to $840 from $770 at Argus
- Cipla Wants to Partner with Eli Lilly (NYSE:LLY) in India
